KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short-term Investments (2016 - 2025)

Abbott Laboratories' Short-term Investments history spans 17 years, with the latest figure at $417.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 18.8% year-over-year to $417.0 million; the TTM value through Dec 2025 reached $417.0 million, up 18.8%, while the annual FY2025 figure was $417.0 million, 18.8% up from the prior year.
  • Short-term Investments for Q4 2025 was $417.0 million at Abbott Laboratories, up from $222.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $483.0 million in Q1 2022 and bottomed at $222.0 million in Q3 2025.
  • The 5-year median for Short-term Investments is $334.5 million (2023), against an average of $337.8 million.
  • The largest annual shift saw Short-term Investments skyrocketed 55.38% in 2021 before it plummeted 36.0% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $450.0 million in 2021, then tumbled by 36.0% to $288.0 million in 2022, then skyrocketed by 32.99% to $383.0 million in 2023, then decreased by 8.36% to $351.0 million in 2024, then rose by 18.8% to $417.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Short-term Investments are $417.0 million (Q4 2025), $222.0 million (Q3 2025), and $331.0 million (Q2 2025).